Titre :

Drugs in focus: proton pump inhibitors

Auteur(s) :

Orel, Rok [Auteur]
Benninga, Marc A. [Auteur]
Broekaert, Ilse J. [Auteur]
Gottrand, fréderic [Auteur]
Service d'endocrinologie pédiatrique [CHU Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Papadopoulou, Alexandra [Auteur]
Ribes-Koninckx, Carmen [Auteur]
Thomson, Mike [Auteur]
Wilschanski, Michael [Auteur]
Thapar, Nikhil [Auteur]

Titre de la revue :

Journal of Pediatric Gastroenterology and Nutrition

Nom court de la revue :

J Pediatr Gastroenterol Nutr

Numéro :

72

Pagination :

645-653

Date de publication :

2021-05-01

ISSN :

1536-4801

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Proton pump inhibitors (PPIs) are amongst the most commonly prescribed drugs in infants and children with the last decades witnessing a dramatic rise in their utilization. Although PPIs are clearly effective when used ...
Lire la suite >Proton pump inhibitors (PPIs) are amongst the most commonly prescribed drugs in infants and children with the last decades witnessing a dramatic rise in their utilization. Although PPIs are clearly effective when used appropriately and have been regarded as safe drugs, there is growing evidence regarding their potential adverse effects. Although, largely based on adult data it is clear that many of these are also relevant to pediatrics. PPI use potentially affects gastrointestinal microbiota composition and function, decreases defence against pathogens resulting in increased risk for infections, interferes with absorption of minerals and vitamins leading to specific deficiencies and increased risk for bone fractures as well as interferes with protein digestion resulting in increased risk of sensitization to allergens and development of allergic diseases and eosinophilic esophagitis. An association with gastric, liver and pancreatic cancer has also been inferred from adult data but is tenuous and causation is not proven. Overall, evidence for these adverse events is patchy and not always compelling. Overall, the use of PPIs, for selected indications with a good evidence base, has significant potential benefit but carries more caution in infants and children. Pediatricians should be aware of the concerns regarding the potential adverse events associated with their use.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:44:27Z
2024-03-04T11:15:20Z